Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)

Published:2017-04 Issue: Volume:75 Page:284-298
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Duffy M.J.,Harbeck N.,Nap M.,Molina R.,Nicolini A.,Senkus E.,Cardoso F.

Funder

Science Foundation Ireland

Strategic Research Cluster Award

BREAST-PREDICT

Clinical Cancer Research Trust

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference112 articles.

1. Tumor markers in breast cancer: European Group of Tumor Markers (EGTM) recommendations;Molina;Tumor Biol,2005

2. Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update;Duffy;Int J Cancer,2013

3. National academy of clinical biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers;Sturgeon;Clin Chem,2008

4. National academy of clinical biochemistry laboratory medicine practice guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers;Sturgeon;Clin Chem,2010

5. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers;Hayes;J Natl Cancer Inst,1996

Cited by 380 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Electrochemical biosensors for early detection of breast cancer;Clinica Chimica Acta;2025-01

2. A triple hormone receptor ER, AR, and VDR signature is a robust prognosis predictor in breast cancer;Breast Cancer Research;2024-09-13

3. Prosigna Assay for Treatment Decisions in Early Breast Cancer: A Decision Impact Study;Journal of Clinical Medicine;2024-09-09

4. Tumor grade and progesterone receptor status in predicting benefit of chemotherapy in high genomic risk breast cancer;Expert Review of Anticancer Therapy;2024-08-22

5. Receptor Discordance in Metastatic Breast Cancer; a review of clinical and genetic subtype alterations from primary to metastatic disease;Breast Cancer Research and Treatment;2024-08-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3